Cite
HARVARD Citation
Horton, J. et al. (2019). "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure". Channels. 13 (1), pp. 1-16. [Online].